A substantial advancement in diabetes treatment is emerging with the introduction of tirzepatide in a 45mg form. This updated formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 target, https://utherpeptidess.com/product/tirzepatide-45mg/